netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 Formulary Chapter 12: Ear, nose and oropharynx - Full Chapter

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

12.03.05  Expand sub section  Treatment of dry mouth
12.03.05  Expand sub section  Local Treatment
Artificial saliva spray
View adult BNF
Formulary The brand in use at each site will depend on local contracts. Contact the pharmacy department for information if required.

  • Glandosane spray
  • Xerotin spray
  • Saliveze spray
  • AS Saliva Orthana

    Biotene Oralbalance saliva replacement gel
    View adult BNF

    Oralieve moisturising mouth gel
    View adult BNF

    BioXtra gel
    View adult BNF

    For Oncology and Palliative Care use only

    Gelclair oral rinse gel
    Restricted Drug Restricted

    For Oncology and Palliative Care use only

    Also available as part of oral mucosa management in  Stevens–Johnson syndrome/toxic epidermal necrolysis as per 2016 BAD guidance

    12.03.05  Expand sub section  Systemic treatment
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Track Changes
    Display tracking information
    click to search
    Link to adult BNF
    click to search
    Link to SPCs
    Scottish Medicines Consortium
    Cytotoxic Drug
    Cytotoxic Drug
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHS England

    Traffic Light Status Information

    Status Description


    Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

    Amber 1

    Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

    Amber 2

    Specialist initiation followed by maintenance prescribing in primary care  

    Amber 3

    Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  


    Specialist and non-specialist initiation  


    Not recommended for prescribing